Literature DB >> 15791040

Left atrial appendage outflow velocity is superior to conventional criteria for predicting of maintenance of sinus rhythm after simple cryoablation of pulmonary vein orifices.

Naoki Isobe1, Koichi Taniguchi, Shigeru Oshima, Hiroshi Kamiyama, Masahiko Ezure, Tatsuo Kaneko, Hiroshi Tada, Hitoshi Adachi, Takuji Toyama, Shigeto Naito, Hiroshi Hoshizaki.   

Abstract

BACKGROUND: We sought to identify factors favoring long-term restoration of sinus rhythm (SR) in patients with atrial fibrillation (AF) who underwent a simple cryoablation of pulmonary vein orifices (PV-cryo) as part of their cardiac surgery. METHODS AND
RESULTS: Of 101 patients with AF undergoing PV-cryo, the 71 in SR at discharge were grouped according to whether they maintained or lost SR (group SR, n = 61, and group AF, n = 10) after an average of 2.3 years. Atrial fibrillation present at discharge (n = 30) persisted during follow up. Comparisons were made to identify preoperative predictive factors, including transthoracic and transesophageal echocardiographic parameters. Of patients discharged from the hospital with SR, 92% (46 of 50) of those with AF duration of 3 years or less were in group SR, as were 92% (23 of 25) of those with left atrial dimension of 50 mm or less, and 93% (37 of 40) of those with average peak left atrial appendage outflow velocities (LAA-V) of at least 30 cm/s. Of 25 patients in group SR who had no paroxysmal AF and did not require antiarrhythmic drugs, all had LAA-V over 20 cm/s. Patients in group AF all had LAA-V under 40 cm/s.
CONCLUSIONS: Left atrial appendage outflow velocities was the best predictor of whether SR was maintained long-term after PV-cryo.

Entities:  

Mesh:

Year:  2005        PMID: 15791040     DOI: 10.1253/circj.69.446

Source DB:  PubMed          Journal:  Circ J        ISSN: 1346-9843            Impact factor:   2.993


  5 in total

Review 1.  2012 HRS/EHRA/ECAS expert consensus statement on catheter and surgical ablation of atrial fibrillation: recommendations for patient selection, procedural techniques, patient management and follow-up, definitions, endpoints, and research trial design.

Authors:  Hugh Calkins; Karl Heinz Kuck; Riccardo Cappato; Josep Brugada; A John Camm; Shih-Ann Chen; Harry J G Crijns; Ralph J Damiano; D Wyn Davies; John DiMarco; James Edgerton; Kenneth Ellenbogen; Michael D Ezekowitz; David E Haines; Michel Haissaguerre; Gerhard Hindricks; Yoshito Iesaka; Warren Jackman; Jose Jalife; Pierre Jais; Jonathan Kalman; David Keane; Young-Hoon Kim; Paulus Kirchhof; George Klein; Hans Kottkamp; Koichiro Kumagai; Bruce D Lindsay; Moussa Mansour; Francis E Marchlinski; Patrick M McCarthy; J Lluis Mont; Fred Morady; Koonlawee Nademanee; Hiroshi Nakagawa; Andrea Natale; Stanley Nattel; Douglas L Packer; Carlo Pappone; Eric Prystowsky; Antonio Raviele; Vivek Reddy; Jeremy N Ruskin; Richard J Shemin; Hsuan-Ming Tsao; David Wilber
Journal:  J Interv Card Electrophysiol       Date:  2012-03       Impact factor: 1.900

2.  Surgical and minimally invasive ablation for atrial fibrillation.

Authors:  Ralph J Damiano; Rochus K Voeller
Journal:  Curr Treat Options Cardiovasc Med       Date:  2006-09

3.  A new era in the surgical treatment of atrial fibrillation: the impact of ablation technology and lesion set on procedural efficacy.

Authors:  Spencer J Melby; Andreas Zierer; Marci S Bailey; James L Cox; Jennifer S Lawton; Nabil Munfakh; Traves D Crabtree; Nader Moazami; Charles B Huddleston; Marc R Moon; Ralph J Damiano
Journal:  Ann Surg       Date:  2006-10       Impact factor: 12.969

Review 4.  Curing atrial fibrillation: Two decades of progress.

Authors:  N A Mark Estes; Ralph J Damiano
Journal:  J Interv Card Electrophysiol       Date:  2007-12       Impact factor: 1.900

5.  Prediction of recurrence after cryoballoon ablation therapy in patients with paroxysmal atrial fibrillation.

Authors:  Demet Menekşe Gerede; Başar Candemir; Veysel Kutay Vurgun; Siamak Mousavi Aghdam; Aynur Acıbuca; Özgür Ulaş Özcan; Hüseyin Göksülük; Celal Kervancıoğlu; Çetin Erol
Journal:  Anatol J Cardiol       Date:  2015-09-15       Impact factor: 1.596

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.